|
1
|
Dissecting the genomic complexity underlying medulloblastoma.
|
Nature
|
2012
|
4.77
|
|
2
|
Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study.
|
Lancet Oncol
|
2009
|
3.07
|
|
3
|
Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian Co-Operative Group for Neuroblastoma.
|
J Clin Oncol
|
2003
|
1.47
|
|
4
|
Prognostic impact of gene expression-based classification for neuroblastoma.
|
J Clin Oncol
|
2010
|
1.43
|
|
5
|
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients.
|
Cancer Res
|
2009
|
1.41
|
|
6
|
MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
|
Pediatr Blood Cancer
|
2010
|
1.40
|
|
7
|
Transcribed-Ultra Conserved Region expression is associated with outcome in high-risk neuroblastoma.
|
BMC Cancer
|
2009
|
1.29
|
|
8
|
Genetic predisposition to familial neuroblastoma: identification of two novel genomic regions at 2p and 12p.
|
Hum Hered
|
2007
|
1.19
|
|
9
|
Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.
|
Carcinogenesis
|
2012
|
1.14
|
|
10
|
Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory.
|
Cancer
|
2008
|
1.06
|
|
11
|
Bone marrow-infiltrating human neuroblastoma cells express high levels of calprotectin and HLA-G proteins.
|
PLoS One
|
2012
|
1.03
|
|
12
|
Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
|
Clin Cancer Res
|
2008
|
1.03
|
|
13
|
Retrospective study of childhood ganglioneuroma.
|
J Clin Oncol
|
2008
|
1.02
|
|
14
|
Weak linkage at 4p16 to predisposition for human neuroblastoma.
|
Oncogene
|
2002
|
1.00
|
|
15
|
Identification and characterization of DNA imbalances in neuroblastoma by high-resolution oligonucleotide array comparative genomic hybridization.
|
Cancer Genet Cytogenet
|
2007
|
0.99
|
|
16
|
Age-dependent accumulation of genomic aberrations and deregulation of cell cycle and telomerase genes in metastatic neuroblastoma.
|
Int J Cancer
|
2012
|
0.99
|
|
17
|
Distinct CpG methylation profiles characterize different clinical groups of neuroblastic tumors.
|
Oncogene
|
2005
|
0.98
|
|
18
|
Role of CXCL13-CXCR5 crosstalk between malignant neuroblastoma cells and Schwannian stromal cells in neuroblastic tumors.
|
Mol Cancer Res
|
2011
|
0.94
|
|
19
|
The Integrated Oncology Program of the Italian Ministry of Health. Analytical and clinical validation of new biomarkers for early diagnosis: network, resources, methodology, quality control, and data analysis.
|
Int J Biol Markers
|
2009
|
0.93
|
|
20
|
Polymorphisms of glutathione-S-transferase M1 and manganese superoxide dismutase are associated with the risk of malignant pleural mesothelioma.
|
Int J Cancer
|
2007
|
0.93
|
|
21
|
A multilocus technique for risk evaluation of patients with neuroblastoma.
|
Clin Cancer Res
|
2011
|
0.92
|
|
22
|
Outcome prediction and risk assessment by quantitative pyrosequencing methylation analysis of the SFN gene in advanced stage, high-risk, neuroblastic tumor patients.
|
Int J Cancer
|
2010
|
0.92
|
|
23
|
Homozygous inactivation of NF1 gene in a patient with familial NF1 and disseminated neuroblastoma.
|
Am J Med Genet A
|
2003
|
0.90
|
|
24
|
Linkage analysis in families with recurrent neuroblastoma.
|
Ann N Y Acad Sci
|
2002
|
0.90
|
|
25
|
Characterisation and validation of insertions and deletions in 173 patient exomes.
|
PLoS One
|
2012
|
0.89
|
|
26
|
High genomic instability predicts survival in metastatic high-risk neuroblastoma.
|
Neoplasia
|
2012
|
0.89
|
|
27
|
Multiple target molecular monitoring of bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors.
|
Pediatr Blood Cancer
|
2011
|
0.89
|
|
28
|
An interferon-sensitive response element is involved in constitutive caspase-8 gene expression in neuroblastoma cells.
|
Int J Cancer
|
2007
|
0.87
|
|
29
|
"DNA-Dressed NAnopore" for complementary sequence detection.
|
Biosens Bioelectron
|
2011
|
0.86
|
|
30
|
Histone chaperone CHAF1A inhibits differentiation and promotes aggressive neuroblastoma.
|
Cancer Res
|
2013
|
0.86
|
|
31
|
Neuroblastoma in the newborn. A study of the Italian Neuroblastoma Registry.
|
Eur J Cancer
|
2009
|
0.85
|
|
32
|
The p53 codon 72 Pro/Pro genotype identifies poor-prognosis neuroblastoma patients: correlation with reduced apoptosis and enhanced senescence by the p53-72P isoform.
|
Neoplasia
|
2012
|
0.85
|
|
33
|
MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
|
Pediatr Blood Cancer
|
2009
|
0.84
|
|
34
|
Inhibition of N-linked glycosylation impairs ALK phosphorylation and disrupts pro-survival signaling in neuroblastoma cell lines.
|
BMC Cancer
|
2011
|
0.84
|
|
35
|
Bone marrow of neuroblastoma patients shows downregulation of CXCL12 expression and presence of IFN signature.
|
Pediatr Blood Cancer
|
2011
|
0.84
|
|
36
|
Transcribed-ultra conserved region expression profiling from low-input total RNA.
|
BMC Genomics
|
2010
|
0.84
|
|
37
|
Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.
|
Virchows Arch
|
2003
|
0.83
|
|
38
|
The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma.
|
Cell Cycle
|
2012
|
0.83
|
|
39
|
Application of microarray-based technology to neuroblastoma.
|
Cancer Lett
|
2005
|
0.82
|
|
40
|
Risk of malignant pleural mesothelioma and polymorphisms in genes involved in the genome stability and xenobiotics metabolism.
|
Mutat Res
|
2009
|
0.82
|
|
41
|
Identification of ALK germline mutation (3605delG) in pediatric anaplastic medulloblastoma.
|
J Hum Genet
|
2012
|
0.81
|
|
42
|
PHOX2B mutations and genetic predisposition to neuroblastoma.
|
Oncogene
|
2005
|
0.81
|
|
43
|
Detection of MYCN amplification and chromosome 1p36 loss in neuroblastoma by cDNA microarray comparative genomic hybridization.
|
Mol Diagn
|
2004
|
0.80
|
|
44
|
Multiple endocrine neoplasias type 2B and RET proto-oncogene.
|
Ital J Pediatr
|
2012
|
0.80
|
|
45
|
Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
|
Clin Cancer Res
|
2004
|
0.80
|
|
46
|
Segmental chromosome aberrations converge on overexpression of mitotic spindle regulatory genes in high-risk neuroblastoma.
|
Genes Chromosomes Cancer
|
2012
|
0.80
|
|
47
|
A novel splice variant of the human dicer gene is expressed in neuroblastoma cells.
|
FEBS Lett
|
2010
|
0.80
|
|
48
|
Chromosome 9q and 16q loss identified by genome-wide pooled-analysis are associated with tumor aggressiveness in patients with classic medulloblastoma.
|
OMICS
|
2011
|
0.79
|
|
49
|
Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells.
|
J Pathol
|
2005
|
0.79
|
|
50
|
Chromosomal aberrations and aneuploidy in oral potentially malignant lesions: distinctive features for tongue.
|
BMC Cancer
|
2011
|
0.79
|
|
51
|
Two regions of deletion in 9p22- p24 in neuroblastoma are frequently observed in favorable tumors.
|
Cancer Genet Cytogenet
|
2002
|
0.79
|
|
52
|
Cyto-morphologic evaluation of bone marrow in infants with disseminated neuroblastoma.
|
J Pediatr Hematol Oncol
|
2012
|
0.78
|
|
53
|
Concomitant DDX1 and MYCN gain in neuroblastoma.
|
Cancer Lett
|
2007
|
0.77
|
|
54
|
c.1810C>T polymorphism of NTRK1 gene is associated with reduced survival in neuroblastoma patients.
|
BMC Cancer
|
2009
|
0.77
|
|
55
|
Glutathione S-transferase polymorphisms and susceptibility to neuroblastoma.
|
Pharmacogenet Genomics
|
2005
|
0.77
|
|
56
|
Epigenetic Silencing of DKK3 in medulloblastoma.
|
Int J Mol Sci
|
2013
|
0.77
|
|
57
|
Oligogenic inheritance in neuroblastoma.
|
Cancer Lett
|
2005
|
0.77
|
|
58
|
Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
|
Pediatr Blood Cancer
|
2014
|
0.77
|
|
59
|
Loss of 10q26.1-q26.3 in association with 7q34-q36.3 gain or 17q24.3-q25.3 gain predict poor outcome in pediatric medulloblastoma.
|
Cancer Lett
|
2011
|
0.77
|
|
60
|
Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors.
|
Clin Cancer Res
|
2005
|
0.76
|
|
61
|
Translational research in hormone-related cancer.
|
Ann N Y Acad Sci
|
2009
|
0.76
|
|
62
|
Gene expression profiling identifies eleven DNA repair genes down-regulated during mouse neural crest cell migration.
|
Int J Dev Biol
|
2011
|
0.76
|
|
63
|
Impact of interleukin-6 -174 G>C gene promoter polymorphism on neuroblastoma.
|
PLoS One
|
2013
|
0.75
|
|
64
|
Constitutional 11q14-q22 chromosome deletion syndrome in a child with neuroblastoma MYCN single copy.
|
Eur J Med Genet
|
2013
|
0.75
|
|
65
|
Topotecan and etoposide combination to test neuroblastoma in pediatric preclinical testing program.
|
Pediatr Blood Cancer
|
2010
|
0.75
|
|
66
|
Research trends for early cancer biomarker detection in Italy: an integrated program in oncology (PIO) survey.
|
Tumori
|
2011
|
0.75
|
|
67
|
Why do cancer omics attract clinicians so much?
|
OMICS
|
2011
|
0.75
|
|
68
|
Treatment of neuroblastoma: from cellular to molecular therapy.
|
Curr Pharm Des
|
2009
|
0.75
|
|
69
|
Simultaneous tumors: acute myeloid leukemia infiltrating mediastinal ganglioneuroblastoma.
|
Pediatr Blood Cancer
|
2011
|
0.75
|